Anacor and TB Alliance sign deal for new target
This article was originally published in Scrip
Executive Summary
Anacor Pharmaceuticals, a biopharmaceutical company developing candidates through proprietary boron chemistry, has signed a drug development deal with the Global Alliance for TB Drug Development (TB Alliance) to develop a new target to treat tuberculosis.